A novel treatment method for ankylosing spondylitis combined with sacroiliac joint bone marrow edema

Original Article | Vol 3 | Issue 2 |  July-December 2023 | page: 41-46 | Leilei Zhang, Xuanye Zhu, Haonan Ling, Wanyi Zhang, Ying Zhang, Youwen Liu, Xiantao Chen

DOI: https://doi.org/10.13107/jrs.2023.v03.i02.101

Author: Leilei Zhang [1], Xuanye Zhu [2], Haonan Ling [1], Wanyi Zhang [1], Ying Zhang [1], Youwen Liu [1], Xiantao Chen [1]

[1] Center of hip Surgery, Henan Luoyang Orthopedic-Traumatological Hospital, Orthopedic Hospital of Henan Province, Luoyang, China.
[2] Henan University of Traditional Chinese Medicine, zhengzhou, China.

Address of Correspondence
Dr. Center of Hip Surgery, Henan Luoyang Orthopedic-Traumatological Hospital, Orthopedic Hospital of Henan Province, No. 82, South Qiming Road, 471002, Luoyang, China.
E-mail: luoyangzhenggu@139.com

Abstract

Objective: To investigate whether high-energy extracorporeal shock wave therapy (ESWT) combined with conventional oral medicine as a potential novel therapeutic approach for the treatment of ankylosing spondylitis (AS)combined with sacroiliac joint bone marrow edema.
Materials & Methods: 40 patients were divided into two groups and were treated with or without ESWT in combination with conventional oral medicine. A visual analog scale (VAS) score of spinal pain, as well as indicators of spinal mobility, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores, inflammatory index (C-reactive protein, blood cell sedimentation rate), and other indicators were compared between the two groups. The Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system was used to evaluate pain and structural damage in the sacroiliac joint.
Results: (1) After one month of treatment (T1), VAS, BASDAI, BASFI, and SPARCC scores were lower in both groups than at the start of treatment (T0) (P < 0.05), with greater decreases observed in the treatment group (P < 0.05). (2) Also, at T1, indicators of spinal mobility for the two groups were improved (P < 0.05). (3) ESR and C-reactive protein levels for the two groups decreased significantly at T1 versus T0 (P < 0.05).
Conclusion: ESWT combined with oral medication can significantly relieve pain and improve clinical functional symptoms for patients with AS. It can also reduce sacroiliac joint bone marrow edema and control the inflammatory reaction in the sacroiliac joint, which represents a novel, effective, reliable, and safe clinical treatment therapeutic method.
Keywords: Ankylosing spondylitis, Sacroiliac joint, extracorporeal shock wave therapy, oral medicine.

References:

1. Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis [J]. Ann Rheum Dis.2010;69(8):1465-1470.
2. Stolwijk C, Van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis[J]. Arthritis CareRes.2016;6(9):132 0-1331.
3. Soroush M, Mominzadeh M, Ghelich Y, et al. Investigation of dardiacdomplications and their incidence in patients with ankylosing spondylitis[J]. Med Arch.2016;70(1):35-38
4. Quaden DH，De Winter LM, Somers V. Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview. Autoim- mun Rev.2016;15( 8) :820-832．
5. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol.2018;30:137–143.
6. Schittenhelm RB, Sivaneswaran S, Lim Kam Sian TC, et al. Human leukocyte antigen (HLA) B27 allotype-specific binding and candidate arthritogenic peptides revealed through heuristic clustering of data-independent acquisition mass spectrometry (DIA-MS) data[J]. Mol Cell Proteomics.2016;15(6): 1867-1876.
7. Heijde D van der, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondylo arthritis. Ann Rheum Dis.2017;76:978–991.
8. Auersperg V, Trieb K. Extracorporeal shock wave therapy: an update. EFORT Open Rev. 2020;5:584–592.
9. D’Agostino C, Romeo P, Lavanga V, et al. Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip. Rheumatol Int.2014;34:1513–8.
10. Kang S,Gao F,Han J,et al. Extracorporeal shock wave treatment can normalize painful bone marrow edema in knee osteoarthritis:A comparative historical cohort study[J].Medicine (Baltimore).2018;97(5):E9796.
11. Vulpiani MC, Vetrano M, Trischitta D, et al. Extracorporeal shock wave therapy in early osteonecrosis of the femoral head: prospective clinical study with long-term follow-up. Arch Orthop Trauma Surg.2012;132: 499–508.
12. Schnurrer-Luke-Vrbanic´ T, Avancini-Dobrovic´ V, Sosa I, et al. Effect of radial shock wave therapy on long bone fracture repair. J Biol Regul Homeost Agents 2018;32:875–9.
13. Brandt J, Bollow M, Häberle J, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy[J]. Rheumatology(Oxford).1999; 38(9): 831-836.
14. Van Der Linden S，Valkenburg H A，Cats A. Evaluation of diagnostic criteria for AS：A proposal for modification of the New York Criteria[J]. Arthritis Rheum.1984;27(4):36 1- 368.
15. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis[J]. Arthritis Rheum.2005;53(5):703-709.
16. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index[J]. J Rheumatol.1994;21(12): 2286-2291.
17. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index[J]. J Rheumatol.1994;21(12): 2281-2285.
18. Braun J, Breban M, Maksymowych W. Therapy for ankylosingspondylitis: new treatment modalities[J].Best Pract Res Clin Rheumatol.2002;16(4): 631-651.
19. Fallahi S. Association of HLA-B27 and its subtypes with ankylosing spondylitis and clinical manifestations of ankylosing spondylitis in different HLA-B27 subtypes: comment on the article[J]. Rheumatol Int.2017;37(10): 1683.
20. Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ.2021;372:m4447.
21. Weber U, Lambert RGW, Østergaard M, et al. The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects[J]. Arthritis Rheum.2010; 62(10): 3048-3058.
22. Machado MA, Moura CS, Ferré F, et al. Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis[J].Rev Saude Publica.2016;50::50.
23. Ward MM, Deodhar A, Gensler L S, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis[J].Arthritis Rheumatol.2019;71(10):1599-1613.
24. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort[J].Ann Rheum Dis.2016;75(12) : 2114-2118．
25. Wanders A, Landewé R, Calin A, et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: Arandomized clinical trial[J]. Arthritis & Rheumatism.2014;52(6):1756-1765.
26. Maffulli N, Longo UG, Denaro V. Novel approaches for the management of tendinopathy [J].J Bone Joint Surg Am.2010;92( 15) : 2604-2613.
27. Mani-Babu S, Morrissey D, Waugh C, Screen H, Barton C. The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: a systematic review. Am J Sports Med.2015;43:752–761.
28. Mariotto S, Cavalieri E, Amelio E, Ciampa AR, Prati AC de, Marlinghaus E, et al. Extracorporeal shock waves: from lithotripsy to anti-inflammatory action by NO production. Nitric Oxide. 2005;12:89–96.
29. Ko JY, Chen HS, Chen LM. Treatment of lateral epicondylitis of the elbow with shock waves[J]. Clin Orthop Relat Res.2001;387(7):60-67.
30. Ciampa AR, Deprati AC, Amelio E, et al. Nitric oxide mediates anti inflammatory action of extracorporeal shock waves[J]. FEBS Lett.2005;579(0):6839-6845.
31. Abe Y, Ito K, Hao K, Shindo T, Ogata T, Kagaya Y, et al. Extracorporeal low-energy shock-wave therapy exerts anti-inflammatory effects in a rat model of acute myocardial infarction. Circ J.2014;78:2915–2925.
32. Wang CJ, Sun YC, Siu KK, et al. Extracorporeal shockwave therapy showssite-specific effects in osteoarthritis of the knee in rats[J].J Surg Res.2013;183(2):612-619.

[Full Text HTML] [Full Text PDF]